Conference Day 2

Day Two

Wednesday June 23 2021

9:50 am Chair’s Opening Remarks

  • Dexiu Bu Senior Principal Scientist, Novartis

Looking at the Preclinical Data for Next Generation BCMA Targeted Therapies

10:00 am Sharing the Development of HPN217: BCMA-targeting TriTAC®


  • TriTAC®: Reviewing characteristics of a novel T-cell engager platform
  • Evaluating HPN217 preclinical in vitro and in vivo data
  • HPN217 Phase 1/2 Trial for Multiple Myeloma

10:30 am Preclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T Cell Therapy for the Treatment of Multiple Myeloma


  • ALLO-605 bears a Turbodomain that confers constitutive, CAR T cellintrinsic cytokine signaling
  • ALLO-605 demonstrated increased potency and persistence, while maintaining a good safety profile
  • Analyze these preclinical results and how they support clinical investigation of ALLO-605 for the treatment of multiple myeloma

11:00 am BCMA-ATAC: Introducing a Novel Mode of Action in Cancer Therapy


  • Antibody-Targeted Amanitin-Conjugates (ATACs) introduce a new mode of action into oncology therapy.
  • The inhibition of RNA polymerase II facilitates killing of dormant tumor cells (CSCs, TICs) and offers new treatment options for difficult to treat cancers and high-risk patients.
  • The unique MoA in combination with a demonstrated safety profile and a biomarker for patient selection might pave the way for accelerated development & approval for patient groups with high therapeutic needs.
  • HDP-101 is a BCMA-ATAC entering Phase I trials for Multiple Myeloma in 2021.


11:30 am Morning Refreshments

Designing Clinical Trials for BCMA Targeted Therapies

12:00 pm Clinical & Translational Insights from the Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel)


  • Evaluating clinical trial results from phase 1 (CRB-401) and phase 2 (MM-001) trials
  • Reviewing clinical correlates of efficacy and safety to ide-cel
  • Reviewing translational correlates of safety and efficacy to ide-cel

12:30 pm Development of TNB-383B, a BCMA x CD3 Bispecific T-cell Redirecting Antibody, for the Treatment of Relapsed/ Refractory Multiple Myeloma

  • Duy Pharm Clinical Development Project Manager, TeneoBio


  • Explore Teneobio’s Discovery Platform that identified our unique anti-CD3
  • Discuss preclinical data that supported activity:toxicity uncoupling by TNB-383B
  • Review clinical data from the escalation part of the FIH phase 1 clinical trial

1:00 pm Antibody Based BCMA Therapies

  • Marc Raab Physician-Scientist & Professor of Medicine at the Heidelberg University Medical Center & Group Leader, German Cancer Research Center (DKFZ)


  • Evaluate how antibody-based immunotherapies targeting BCMA show great promise in relapsed/refractory multiple myeloma
  • The antibody-drug conjugate belantamab mafodotin has recently been approved for late line therapy and combination regimens in earlier lines are currently under clinical investigation
  • Explore how T-cell engagers, such as BCMAxCD3 bispecific antibodies have produced high response rates in late line patients in early clinical trials and appear to challenge cell-based therapies as an off-the-shelf alternative

1:30 pm Lunch

Delving into the Rationale of Combinations Studies for BCMA Therapies

2:30 pm Session Reserved for JnJ

3:00 pm Potential for Combination Strategies Using an Off-the-shelf Allogeneic CAR T in Multiple Myeloma

  • Chris Heery Chief Medical Officer, Precision BioSciences, Inc


  • PBCAR269A is an allogeneic, off-the-shelf, BCMA targeted CAR T cell product made from healthy donor apheresis products using ARCUS gene editing technology
  • The ready availability of PBCAR269A opens up opportunities for maximize therapeutic benefit while minimizing toxicity
  • This talk will discuss the potential synergist approach that could be achieved with combination strategies to maximize efficacy and limit toxicity

3:30 pm The Impact of Antigen Density & Stability on the Efficacy of BCMA Targeted Therapeutics

  • Damian Green Associate Professor - Clinical Research Division, Fred Hutchinson Cancer Research Center


• Review preclinical findings that inform the use of gamma secretase
inhibitors in combination with BCMA targeted therapy
• Discuss the experience from first-in-human combinations of gamma
secretase inhibitor therapy with BCMA CAR-T Cells
• Discuss the impact of BCMA surface density and stability on treatment

4:00 pm Afternoon Break

Looking at the Past & Protecting the Future; Patient Perspective

5:00 pm Global Competition in BCMA-targeted Immunotherapy

  • Frank Fan Co-Founder & Chief Scientific Officer, Legend Biotech


  • Multiple myeloma remain as an “incurable” cancer?
  • Clinical progress of CAR-T therapy in multiple myeloma
  • Competitive landscape of BCMA targeted therapy in early-stage commercial development

5:30 pm Chair’s Closing Remarks

  • Dexiu Bu Senior Principal Scientist, Novartis